Faes Farma : Good Q4 2021 results above expectations on higher sales of traditional products
>Q4 2021 results above expectations due to slightly higher sales - Total Q4 2021 revenues reached € 104m (+16% y-o-y and similar to +15% in previous quarter), with sales of traditional products in Spain accelerating the sales recovery (+14% y-o-y in Q4 2021 vs +5% in Q3) although sales in Portugal declined (-8% y-o-y in Q4 2021 vs +19% in Q3 2021), reflecting the end of the licensing contract with Tillots. Sales recovery was also very strong for LatAm and exports (+38...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.